Espicom


The Pharmaceutical Market: Gabon

Published 31 October 2014

  • 47 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
The Pharmaceutical Market: Gabon

Table of Contents

BMI Industry View
7
SWOT
10
Industry Forecast
11
Pharmaceutical Market Forecast
11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Gabon 2010-2018)
12
Healthcare Market Forecast
13
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Gabon 2010-2018)
15
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Gabon 2010-2018)
15
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Gabon 2010-2018)
15
Industry Risk Reward Ratings
16
Middle East & Africa Risk/Reward Ratings
16
Gabon Risk/Reward Ratings
24
Rewards
24
Risks
24
Market Overview
25
Industry Trends And Developments
26
Epidemiology
26
Regulatory Development
29
Competitive Landscape
31
Pharmaceutical Sector
31
Demographic Forecast
34
Gabon Demographic Forecast
34
Table: Gabon's Population By Age Group, 1990-2020 ('000)
35
Table: Gabon's Population By Age Group, 1990-2020 (% of total)
36
Table: Gabon's Key Population Ratios, 1990-2020
37
Table: Gabon's Rural And Urban Population, 1990-2020
37
Glossary
38
Methodology
40
Pharmaceutical Expenditure Forecast Model
40
Healthcare Expenditure Forecast Model
40
Notes On Methodology
41
Risk/Reward Ratings Methodology
42
Ratings Overview
43
Table: Pharmaceutical Risk/Reward Ratings Indicators
43
Indicator Weightings
44
OVERVIEW OF THE PHARMACEUTICAL MARKET IN GABON

There are emerging downside risks to our Gabon pharmaceutical and healthcare expenditure forecasts. Economic expansion is stagnating, which could lead to political instability. The country's much-praised universal healthcare system is undergoing reforms, and the infectious disease burden remains intractably high. Commercial opportunities in the medical sector will be limited to low-value, moderate-volume generic drugs and very low-volume, high - value branded medicines.

Headline Expenditure Forecasts

Pharmaceuticals: XAF67.7bn (US$131mn) in 2012 to XAF72.0bn (US$137mn) in 2013; +6.4% in local currency and 5% in US dollar terms. Market size and forecast revised down compared with Q113 update due to new historic data and a less optimistic macroeconomic outlook.

Healthcare: XAF286bn (US$551mn) in 2012 to XAF303bn (US$577mn) in 2012; +6.0% in local currency and +3.0% in US dollar terms. Market size and forecast revised down compared with Q113 update due to new historic data and a less optimistic macroeconomic outlook.

Risk/Reward Rating

Gabon's Pharmaceutical Risk/Reward Rating (RRR) score for Q213 is unchanged from the previous quarter. This is also the case for all other countries in BMI ' s proprietary system , which ranks pharmaceutical markets according to attractiveness to multinational drugmakers. A minor re-weighting of one of the RRR components is being implemented to improve the tool, and the adjusted scores for all markets will be published in the Q313 updates of the Pharmaceuticals & Healthcare reports. Gabon has a RRR score of 40. 0 out of 100, m making it the 20th most attractive pharmaceutical market in the Middle East and Africa.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%